PoliticsItalySwedenEU

Eating meat makes you resistant to antibiotics

15.03.2012 - Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European Centre for Disease Prevention and Control (ECDC).

High resistance levels were recorded to ampicillin, tetracyclins and sulfonamides in Salmonella isolates from humans (13%-75%), whereas resistance to third-generation cephalosporins and fluoroquinolones remained low (0.2%-7%). In Campylobacter isolates from human cases, resistance to ampicillin, ciprofloxacin, nalidicic acid, and tetracyclins were high (21%-84%), while resistance to erythromycin was recorded at low to moderate levels (0.5%-25%). Most resistances are transmitted by meat consumption from animals that have become resistant to antibiotics, according to the „EU report on antimicrobial resistnce in zoonotic bacteria affecting humans, animals, and foods.“ The highest occurrence to ciproflaxin was noted in Salmonella from turkeys (28%) followed by fowl and broiler meat (24%). High resistance, ranging from 37% to 84% was also observed in Campylobacter isolates from fowl, pigs, and cattle. Methcillin-resistant Staphylococcus aureus (MRSA) in food and animals occurred at levels varying from 0% to 79%, and was most commonly found in turkeys. The surveillance data, which form the base of the report, were submitted in 2010 by 26 EU member states.

http://www.european-biotechnology-news.com/news/news/2012-01/eating-meat-makes-you-resistant-to-antibiotics.html

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.47 CHF27.03%
  • BIOFRONTERA2.07 EUR4.02%
  • FORMYCON17.40 EUR3.02%

FLOP

  • STRATEC BIOMEDICAL43.50 EUR-3.59%
  • MEDIGENE4.55 EUR-1.94%
  • EVONIK30.88 EUR-1.66%

TOP

  • WILEX3.15 EUR47.9%
  • CYTOS0.47 CHF38.2%
  • EVOLVA1.69 CHF18.2%

FLOP

  • MOLOGEN5.27 EUR-13.7%
  • SANTHERA97.20 CHF-11.4%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA97.20 CHF2424.7%
  • WILEX3.15 EUR400.0%
  • FORMYCON17.40 EUR122.2%

FLOP

  • CYTOS0.47 CHF-83.4%
  • MOLOGEN5.27 EUR-57.2%
  • PAION2.09 EUR-55.5%

No liability assumed, Date: 04.03.2015